Investors

EastGate Biotech Provides Update on investment from Genluiching Mining Corporation

July 24, 2018 by admin

EastGate to receive the first non-dilutive investment tranch from the total funding up to $5 million USD as per the terms of the Definitive Agreement.

Read more

EastGate Biotech Expands Indications of Liquid Insulin Mouth Rinse Solution to Alzheimer’s Disease with Joint Venture Partner Genome Pharmaceuticals

June 28, 2018 by admin

Genome Pharma is the parent company of Netris/Origin BioPharmaceuticals the company’s Joint Venture Partner

Read more

EastGate Biotech Unveils Manufacturing Plans in an MOU with Mystic Pharmaceuticals Limited for its Liquid Insulin Mouth Rinse Solution

June 21, 2018 by admin

Focus on the manufacturing of the company’s liquid insulin mouth rinse solution for specific markets. Presently, EastGate is developing its insulin mouth rinse in the Philippines, Pakistan, and Europe through its JV with Nico Innovapharma.

Read more

Morphs into Global Licensing Play with $36 Million in Milestone Payments

June 20, 2018 by admin

Morphs into Global Licensing

Read more

EastGate Biotech Strikes Investment and Licensing Collaboration with Nico Innovapharma for Liquid Insulin Mouth Rinse Solution for the European Market

June 20, 2018 by admin

EastGate Biotech Strikes Investment and Licensing Collaboration with Nico Innovapharma for Liquid Insulin Mouth Rinse Solution for the European Market

Read more

EastGate Biotech Enters into a Financial Agreement

May 2, 2018 by admin

WEST CALDWELL, NJ and TORONTO, May 2, 2018 (AccessNewswire-) EastGate Biotech Corp. (PinkSheets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, announced that it had entered into a Financial Loan Agreement with a high net worth individual on April 20, 201

Read more

EastGate Biotech Announces Joint Venture with Netris/Origin Biopharmaceuticals for Pakistani Market

April 17, 2018 by admin

WEST CALDWELL, NJ and TORONTO, April 17, 2018 (AccessNewswire-) EastGate Biotech Corp. (PinkSheets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, announced a joint venture agreement with Netris /Origin Biopharmaceuticals (Netris/Origin) to conduct clinical trials, register, and commercialize the Netris/Origin pipeline for the Pakistani market.

Read more

EastGate Biotech Announces Definitive Agreement with Genluiching Mining Corporation.

April 11, 2018 by admin

WEST CALDWELL, NJ and TORONTO, April 10, 2018 (AccessNewswire-) EastGate Biotech Corp. (PinkSheets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, announced a definitive agreement with Genluiching Mining Corporation. As per the previously announced Memorandum of Understanding Genluiching Mining will investment up to $5 million USD in tranches. The first tranche will be expected sometime in May.

Read more

EastGate Biotech Corp., CEO Anna Gluskin and President, Rose Perri Visit Uptick Newswire’s “Stock Day” with Everett Jolly

March 30, 2018 by admin

EastGate Biotech Corp., CEO Anna Gluskin and President, Rose Perri Visit Uptick Newswire’s “Stock Day” with Everett Jolly

Read more

EastGate Biotech Announces that it has reached a Definitive Settlement Agreement with Northbridge Financial Inc..

March 23, 2018 by admin

EastGate Biotech Announces that it has reached a Definitive Settlement Agreement with Northbridge Financial Inc.. The Share Reserve with Transfer Agent has been cancelled and all remaining shares have been returned to EastGate Biotech. WEST CALDWELL, NJ and TORONTO, March 22, 2018 (AccessNewswire-) EastGate Biotech Corp. (PinkSheets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, announced today that it has reached a definitive settlement agreement with Northbridge Financial. Last year EastGate entered into a series of 3(a)(10) exemptions with Northbridge Financial detailed in 2 Form 8-K filings. Northbridge Financial released all remaining debt from the Settlement Agreement dated May 9, 2017 between Northbridge Financial Inc. and EastGate Biotech Corp.. As a result NorthBridge Financial has released all remaining shares in the reserve with the EastGate’s Transfer Agent back to the company.

Read more
RSS Icon